AlphaValue/Baader Europe Cuts Sanofi Price Target After Scrapped Late-Stage Rare Neurological Disease Trial
AlphaValue/Baader Europe reduced its price target for Sanofi (SAN.PA) after the French drugmaker discontinued the late-stage clinical study of riliprubart in chronic inflammatory demyelinating polyneuropathy. "Had Riliprubart cleared regulatory hurdles, it could have been a multi-blockbuster product for Sanofi. A series of R&D setbacks over the last [two to three years] has shaken our confidence in the firm's innovation capability," analysts said Tuesday. "Overall, we do not see a meaningful catalyst for Sanofi in the near-term, and investors might be better off looking at other options." As such, the research firm cut the buy-rated stock's price target by 6.79% to 97.7 euros. "The upside potential on the French giant is largely owing to 1/ the optionality of chasing external innovation and 2/ the possibility of decent execution of current pipeline, both backed by still [five to six] years of patent protected life for the lynchpin immunology drug Dupixent (c.36% of 2025 sales), relative stability of vaccines business, and encouraging growth of drugs launched in the recent years," the note said. On the earnings side, AlphaValue/Baader Europe forecasts full-year 2026 sales of.
AlphaValue/Baader Europe reduced its price target for Sanofi (SAN.PA) after the French drugmaker discontinued the late-stage clinical study of riliprubart in chronic inflammatory demyelinating polyneuropathy. "Had Riliprubart cleared regulatory hurdles, it could have been a multi-blockbuster product for Sanofi.
A series of R&D setbacks over the last [two to three years] has shaken our confidence in the firm's innovation capability," analysts said Tuesday. "Overall, we do not see a meaningful catalyst for Sanofi in the near-term, and investors might be better off looking at other options." As such, the research firm cut the buy-rated stock's price target by 6.79% to 97.7 euros. "The upside potential on the French giant is largely owing to 1/ the optionality of chasing external innovation and 2/ the possibility of decent execution of current pipeline, both backed by still [five to six] years of patent protected life for the lynchpin immunology drug Dupixent (c.36% of 2025 sales), relative stability of vaccines business, and encouraging growth of drugs launched in the recent years," the note said.
On the earnings side, AlphaValue/Baader Europe forecasts full-year 2026 sales of.